Early biomarkers and imaging markers to predict AMD progression
Official title: Epidemiology of Biomarkers of AMD Progression
Funded at Doheny Eye Institute · NIH-11398025 · Data updated 2026-11-12
This project looks at how advanced eye imaging and biomarkers can identify which people with early age-related macular degeneration are likely to progress, so future treatments can be tested sooner.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Doheny Eye Institute NIH-funded |
| Lab location | 1 site (Pasadena, UNITED STATES) |
| Project start | September 30, 2021 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $586,145 |
| NIH project number | 5R01EY030614-05 |
| Project ID | NIH-11398025 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with age-related macular degeneration who are in early or intermediate stages and may be at risk of progression, including individuals represented by diverse imaging phenotypes.
✕Less likely to help
Patients with advanced geographic atrophy or late-stage AMD at enrollment may not directly benefit from this imaging biomarker-focused work.
What this research studies
Researchers will study granular imaging features from modern eye scans (like OCT and OCT-A) to create a more precise staging system for AMD progression. The goal is to pinpoint who should be enrolled in future interventional trials by identifying biomarkers and endpoints that reflect early-to-late disease changes. The work will compare new imaging-based risk markers with older, film-era standards to improve patient selection and trial timing. This study uses human participant data from individuals at risk of AMD progression and may inform future clinical studies seeking to slow or prevent geographic atrophy.
Why it matters
Potential benefit: Better identification of patients at risk could enable earlier, more effective interventions and accelerate development of treatments for AMD.
How similar studies have gone: Previous large AMD studies have identified imaging markers linked to progression, but this project seeks more granular, OCT-based markers for earlier intervention.
Where this research is happening
-
Doheny Eye Institute
Pasadena, United States Active
Researchers
- Principal investigator: Sadda, Srinivas R — Doheny Eye Institute
- Study coordinator: Sadda, Srinivas R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.